Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(1)
Other(3)

Detailed Status

unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

unknown375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_1

PRECISE CURATE.AI Pilot Clinical Trial

NCT04522284
unknownphase_3

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

NCT05669092
unknownphase_2

XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

NCT03511170
terminatedphase_2

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

NCT00127036

Clinical Trials (4)

Showing 4 of 4 trials
NCT04522284Phase 1

PRECISE CURATE.AI Pilot Clinical Trial

Unknown
NCT05669092Phase 3

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Unknown
NCT03511170Phase 2

XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Unknown
NCT00127036Phase 2

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4